All In Biotech

Drug Trial Radar · NCT07122648

Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis

A Prospective, Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase 2 Trial to Evaluate the Efficacy, Safety of PN-101(Mitochondria Isolated From Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells) Single Dose in Patients With Refractory Polymyositis or Dermatomyositis

Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Dec 2025

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Paean Biotechnology Inc.Industry
Sponsor type
Industry
First posted
Aug 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The efficacy of PN-101 in subjects with polymyositis or dermatomyositis will be evaluated at Week 12 using IMACS-TIS in comparison with the placebo control group. The safety and efficacy will be evaluated following administration of PN-101 to subjects with polymyositis or dermatomyositis, in comparison with the placebo group

Conditions

  • Polymyositis
  • Dermatomyositis

Interventions

  • placeboBiological

    Participants will receive a single IV dose of 300 µg of placebo

  • PN-101Biological

    Participants will receive a single IV dose of 300 µg of PN-101

  • PN-101Biological

    Participants will receive a single IV dose of 600 µg of PN-101.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. International Myositis And Clinical Studies group-Total Improvement Score (IMACS-TIS)Time frame: 12 weeks after the IP administration

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Kyung Hee University Medical Center

    Seoul, South Korea

  • Seoul National University

    Seoul, South Korea

  • Soon Chun Hyang University Hospital Seoul

    Seoul, South Korea

  • Chung-Ang University Hospital

    Seoul, South Korea

  • Chung-Ang University Gwang Myeong Hospital

    Gwangmyeong, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.